In-depth chracterization of immune checkpoints in the tumor microenvironmentOur extensive validation and advanved technical support ensures that all of our IHC-P-validated antibodies can be used for fluorescent multiplex IHC.
This application note focuses on the advantages of multiplexing with our validated antibodies against targets relevant in cancer and immuno-oncology: Immune checkpoint proteins and T cell exhaustion markers. Examples of mIHC data obtained in FFPE ovarian carcinoma and NSCLC samples. Protocol optimization steps for multiplexing with six targets.
This poster focuses on using highly multiplexed assays to examine immune checkpoints and biomarkers for immunotherapy. Multiplex IHC panels consisting of up to six targets plus DAPI were constructed and validated in various tumor types.
This application note focuses on how examining suppressive myeloid cells and other markers of the TME is made possible by multiplexing with IHC-validated antibodies.
Preclinical studies leverage syngeneic mouse models for the testing and design of immune checkpoint therapies. This new application note describes the use of mouse-reactive, IHC-validated antibodies in fluorescent multiplexed immunohistochemistry (mIHC) studies.
This application note focuses on protocol considerations for signal amplification in mIHC to detect PD-L1, VISTA, B7-H4, CD8α, and Cytokeratin.
A mIHC panel focusing on exhausted T cell markers was constructed and used to stain various tumor types. Highly detailed images of the tumor microenvironment were obtained and quantified in order analyze patterns of co-expression of co-inhibitory immune checkpoint receptors and to phenotype the immune infiltrate. A myriad of distinct patterns of co-expression of immune checkpoint receptors were observed, underscoring the need for highly multiplexed assays.